Bioequivalence trial of orally disintegrating mirtazapine tablets and conventional oral mirtazapine tablets in healthy volunteers

Clinical Drug Investigation

Volumn 21, Issue 6, 2001, Pages 437-442

  Van Den Heuvel, M W ^a,b   Kleijn, H J ^a   Peeters, P A M ^a  

^a NV ORGANON   (Netherlands)

^b NV Organen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GOOD CLINICAL PRACTICE; HUMAN; HUMAN EXPERIMENT; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SOMNOLENCE; TABLET; VERTIGO;

EID: 0034978301     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121060-00007     Document Type: Article

References (4)

1. Hirschfeld RMA. Long-term drug treatment of unipolar depression. Int Clin Psychopharmacol 1996; 11: 211-7
2. Kasper S. Clinical efficacy of mirtazapine: a review of metaanalyses of pooled data. Int Clin Psychopharmacol 1995; 10: 25-35
3. Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms: results from a placebocontrolled trial. Drug Invest 1994; 8: 339-44
4. Mattilla M, Jääskeläinen J, Järvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995; 5: 441-6